TY - JOUR
T1 - The Cognitive Ageing, Nutrition and Neurogenesis (CANN) trial
T2 - Design and progress
AU - Irvine, Michael A.
AU - Scholey, Andrew
AU - King, Rebecca
AU - Gillings, Rachel
AU - Vauzour, David
AU - Demichele, Stephen J.
AU - Das, Tapas
AU - Wesnes, Keith A.
AU - Sutton, Brad P.
AU - Cassidy, Aedin
AU - Pipingas, Andrew
AU - Potter, John F.
AU - Johnson, Glyn
AU - White, David
AU - Larsen, Ryan
AU - Cohen, Neal J.
AU - Minihane, Anne Marie
N1 - Funding Information:
Conflicts of Interest: The research was funded in part by Abbott Nutrition via a Center for Nutrition, Learning, and Memory (CNLM) grant to the University of Illinois , which in turn awarded a research grant to the authors through a competitive peer reviewed process. Study foods were provided free of charge by Abbott Nutrition (Columbus, OH, USA). In addition, A.C. received funding from the US Highbush Blueberry Council . A.-M.M received funding from Unilever Best Foods . A.P. received funding and consultancy fees from Biostime, Blackmores, DSM, LifeVantage, Novasel Australia, Enzo Nutraceuticals, and Swisse Wellness . A.S. received funding from Arla Foods, Bayer, Kemin Foods, Nutricia-Danone, and Verdure Sciences. D.W. was funded by Arla Foods and Bayer. B.S. and N.C. were funded by Abbott Nutrition , Center for Learning and Memory, University of Illinois . D.V. received funding from the Florida Department of Citrus and the Cranberry Institute . K.W. is a consultant for Bracket, who provided the Cognitive Drug Research test battery for this study. T.D., S.D., R.G., M.I., G.J., R.K., R.L., and J.P. have no conflicts of interest to declare.
Funding Information:
Conflicts of Interest: The research was funded in part by Abbott Nutrition via a Center for Nutrition, Learning, and Memory (CNLM) grant to the University of Illinois, which in turn awarded a research grant to the authors through a competitive peer reviewed process. Study foods were provided free of charge by Abbott Nutrition (Columbus, OH, USA). In addition, A.C. received funding from the US Highbush Blueberry Council. A.-M.M received funding from Unilever Best Foods. A.P. received funding and consultancy fees from Biostime, Blackmores, DSM, LifeVantage, Novasel Australia, Enzo Nutraceuticals, and Swisse Wellness. A.S. received funding from Arla Foods, Bayer, Kemin Foods, Nutricia-Danone, and Verdure Sciences. D.W. was funded by Arla Foods and Bayer. B.S. and N.C. were funded by Abbott Nutrition, Center for Learning and Memory, University of Illinois. D.V. received funding from the Florida Department of Citrus and the Cranberry Institute. K.W. is a consultant for Bracket, who provided the Cognitive Drug Research test battery for this study. T.D., S.D., R.G., M.I., G.J., R.K., R.L., and J.P. have no conflicts of interest to declare.
Publisher Copyright:
© 2018
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2018
Y1 - 2018
N2 - Introduction: The Cognitive Ageing, Nutrition and Neurogenesis trial hypothesizes that a combined intervention with long-chain n-3 polyunsaturated fatty acids (n-3) and cocoa flavan-3-ols (FLAV) will mitigate the cognitive decline anticipated to naturally occur over 1 year in older adults. Methods: In a double-blinded, placebo-controlled parallel design, 259 individuals with mild cognitive impairment or subjective memory impairment were randomized to a control or n-3 FLAV group (1.5 g docosahexaenoic acid + eicosapentaenoic acid and 500 mg n-3 FLAV daily) for 12 months. Cognition was measured at 0, 3, and 12 months. The primary end-point is hippocampus-sensitive cognitive function (e.g., number of false-positives on the Picture Recognition Task of the Cognitive Drug Research test battery). Secondary outcomes include additional cognitive measures, brain atrophy and blood flow (assessed by magnetic resonance imaging), vascular function, circulating biomarkers of cardiovascular and cognitive health, gut microflora, red blood cell fatty acid status, and urine flavan-3-ol metabolites. Results: Screening began in 2015, with all baseline visits completed in March 2017. The intervention was finished in March 2018. Discussion: Cognitive Ageing, Nutrition and Neurogenesis aims to identify an effective diet-based intervention to prevent or delay cognitive impairment in cognitively at-risk individuals, which could ultimately contribute to a reduced population burden of dementia. Clinicaltrials.gov: NCT02525198.
AB - Introduction: The Cognitive Ageing, Nutrition and Neurogenesis trial hypothesizes that a combined intervention with long-chain n-3 polyunsaturated fatty acids (n-3) and cocoa flavan-3-ols (FLAV) will mitigate the cognitive decline anticipated to naturally occur over 1 year in older adults. Methods: In a double-blinded, placebo-controlled parallel design, 259 individuals with mild cognitive impairment or subjective memory impairment were randomized to a control or n-3 FLAV group (1.5 g docosahexaenoic acid + eicosapentaenoic acid and 500 mg n-3 FLAV daily) for 12 months. Cognition was measured at 0, 3, and 12 months. The primary end-point is hippocampus-sensitive cognitive function (e.g., number of false-positives on the Picture Recognition Task of the Cognitive Drug Research test battery). Secondary outcomes include additional cognitive measures, brain atrophy and blood flow (assessed by magnetic resonance imaging), vascular function, circulating biomarkers of cardiovascular and cognitive health, gut microflora, red blood cell fatty acid status, and urine flavan-3-ol metabolites. Results: Screening began in 2015, with all baseline visits completed in March 2017. The intervention was finished in March 2018. Discussion: Cognitive Ageing, Nutrition and Neurogenesis aims to identify an effective diet-based intervention to prevent or delay cognitive impairment in cognitively at-risk individuals, which could ultimately contribute to a reduced population burden of dementia. Clinicaltrials.gov: NCT02525198.
KW - Cocoa flavan-3-ols
KW - Cognition
KW - Dementia
KW - Docosahexaenoic acid
KW - Eicosapentaenoic acid
KW - Hippocampus
KW - Magnetic resonance imaging
KW - Mild cognitive impairment
KW - Subjective memory impairment
UR - http://www.scopus.com/inward/record.url?scp=85056169124&partnerID=8YFLogxK
U2 - 10.1016/j.trci.2018.08.001
DO - 10.1016/j.trci.2018.08.001
M3 - Article
C2 - 30426067
AN - SCOPUS:85056169124
SN - 2352-8737
VL - 4
SP - 591
EP - 601
JO - Alzheimer's & Dementia: Translational Research & Clinical Interventions
JF - Alzheimer's & Dementia: Translational Research & Clinical Interventions
ER -
